Studies Upon the Toxicity of Polyethylene Glycol Coated Lipid Vesicles: Acute Hemodynamic Effects, Pyrogenicity and Complement Activation

References

• Utkhede D., Tilcock C. Effect of lipid dose on the biodistribution and clearance kinetics of PEG-coated technetium labeled lipid vesicles. Journal of Liposome Research 1998, in press
   Google Scholar
• Storm G., Oussoren C., Peeters P. A.M., Barenholz Y. Tolerability of Liposomes in vivo. Liposome Technology, G. Gregoriadis. CRC Press, Boca Raton, FL 1993; Vol. III: 345–383
   Google Scholar
• Marjan J., Xie Z., Devine D. V. Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochimica et Biophysica Acta 1994; 1192(1)35–44
   PubMed Web of Science ®Google Scholar
• Devine D. V., Wong K., Serrano K., Chonn A., Cullis P. Liposomes-complement interactions in rat serum: implications for liposome survival studies. Biochimica et Biophysica Acta 1994; 1191(2)43–51
   PubMedGoogle Scholar
• Liu D., Liu F., Song Y. K. Recognition and clearance of liposomes containing phosphatidyl serine are mediated by serum opsonin. Biochimica et Biophysica Acta 1995; 1235: 140–146
   PubMed Web of Science ®Google Scholar
• Oja C. D., Semple S. C., Chonn A., Cullis P. R. Influence of dose on liposome clearance: critical role of blood proteins. Biochimica et Biophysica Acta 1996; 1281: 31–37
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., Kaufmann B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Cancer Research 1994; 54: 987–992
   PubMed Web of Science ®Google Scholar
• Sturzl M., Zietz C., Eisenburg B., Goebel F. D., Gillitzer R., Hofschneider P. H., Bogner J. R. Liposomal doxorubicin in the treatment of Kaposi's sarcoma: clinical, histological and cell biological evaluation. Research in Virology 1994; 145(3)261–269
   PubMedGoogle Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncology 1995; 13(7)1777–1785
   PubMed Web of Science ®Google Scholar
• Goebel F. D., Goldstein D., Goos M., Jablonowski H., Stewart J. S. Efficacy and safety of Stealth liposomal doxorubicin in AIDS related Kaposi's sarcoma. The International SL-DOX Study Group. Brit J Cancer 1996; 73(8)989–994
   PubMedGoogle Scholar
• Alberts D. S., Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(Suppl 4)30–35
   PubMed Web of Science ®Google Scholar
• Working P. K., Dayan A. D. Pharmacological-Toxicological Expert Report. Caelyx™. (Stealth Liposomal Doxorubicin HCl) Human and Exper Toxicol 1996; 15(9)752–785
   Google Scholar
• Szebeni J., Spielberg H., Cliff R. O., Wassef N. M., Rudolph A. S., Alving C. R. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1. Artifical Cell, Blood Substitutes, and Immobilization Biotechnology 1997; 25(4)347–355
   PubMed Web of Science ®Google Scholar
• Harashima H., Sakata K., Funato K., Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending upon the size of the vesicles. J Pharmaceutical Research 1994; 11: 402–406
   PubMed Web of Science ®Google Scholar
• Sone Y., Nicolaysen A., Staub N. C. Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiology 1997; 83(5)1499–1507
   PubMedGoogle Scholar
• Allen T. M., Smuckler E. A. Liver pathology accompanying chronic liposome administration in mice. Research. Communications in Chemical Pathology and Pharmacology 1985; 65: 185–190
   Google Scholar
• Szebeni J., Wassef N. M., Rudolph A. S., Alving C. R. Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. Artifical Cell, Blood Substitutes, and Immobilization Biotechnology 1995; 23(3)355–363
   PubMed Web of Science ®Google Scholar
• Guencheva G., Popova P., Daivkova G., Mincheva V., Mihailova S., Bogdanov A., Pacelli E., Auteri A. Determination of cytokine release after in vivo and in vitro administration of Deodan (a preparation from Lactobacillus bulgarius “LB51”) by the rabbit pyrogen test. Immunopharmacology 1992; 14(8)1429–1436
   Google Scholar
• Minano F. J., Fernandez-Alonso A., Benamar K., Myers R. D., Sancibrian M., Ruiz R. M., Armengol J. A. Macrophage inflammatory protein-1b (MIP-1b) produced endogenously in brain during E. coli fever in rats. European Journal of Neuroscience 1996; 8: 424–428
   PubMedGoogle Scholar
• Pyrogen Testing. US Pharmacopeia National Formulary (USPNF), 22nd Edition. 1990; 1515–1518
   Google Scholar
• Rabinovici R., Rudolph A. S., Vernick J., Feuerstein G. Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical and hematologic responses. Critical Care Medicine 1994; 22(3)480–485
   PubMedGoogle Scholar
• Weary M. Pyrogen testing of parenteral products-status report. Parenteral Science and Technology 1984; 38(1)20–23
   PubMedGoogle Scholar
• Cradock J. C., Vishnuvajjala B. R., Chin T. F., Hochstein H. D., Ackerman S. K. Uridine-induced hyperthermia in the rabbit. Journal of Pharmacy and Pharmacology 1986; 38: 226–229
   PubMedGoogle Scholar
• Dinarello C. A., Elin J., Chedid L., Wolff S. M. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. Journal of Infectious Disease 1978; 138(6)760–767
   PubMedGoogle Scholar
• Kanter P. M., Bullard G. A., Pilkiewicz F. G., Mayer L. D., Cullis P. R., Pavelic Z. P. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 1993; 7(1)85–96
   PubMedGoogle Scholar
• Amsterdam E. A., Stahl G. L., Pan H-L., Rendig S. V., Flethcher M. P., Longhurst J. C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. American Journal of Physiology 1995; 268: H448–H457
   Google Scholar
• Gardinali M., Conciato L., Cafaro C., Agostoni A. Complement system in coronary heart disease: a review. Immunopharmacology 1995; 30: 105–117
   PubMedGoogle Scholar
• Steurer G., Yang P., Rao V., Mohl W., Glogar D., Smetana R. Acute myocardial infarction, reperfusion injury and intravenous magnesium therapy: basic concepts and clinical implications. American Heart Journal 1996; 132: 478–82
   PubMedGoogle Scholar
• Sodee D. B. Special in vitro procedures. Principles and Practice of Nuclear Medicine, P. J. Early, D. B. Sodee. Mosby, St. Louis, Missouri 1995; 725–738
   Google Scholar
• Kawana S., Wachi J., Nakayama M., Namiki A. Comparison of haemodynamic changes induced by sevflurane and halothane in pediatric patients. Canadian Journal of Anesthesia 1995; 42(7)603–607
   PubMedGoogle Scholar